ASCO 2021 Ovarian Cancer

Novel drug combination for recurrent ovarian cancer

Mirvetuximab soravtansine, a folate receptor-targeting antibody-drug conjugate, in combination with bevacizumab, demonstrated impressive anti-cancer activity in the phase 1b FORWARD II trial.  Mirvetuximab soravtansine (MIRV) is...

Read More

The Insider’s Guide to ASCO 2021: Ovarian Cancer

The ASCO Annual Meeting enters its second year in a virtual setting June 4-8, 2021, to ensure the safety and health of attendees while delivering groundbreaking science in oncology and timely information on clinical application...

Read More

For latest news and updates
Email-id is invalid